Gereç ve Yöntem: Toplam 60 kişi (20 MDB hastası, 40 sağlıklı kontrol) çalışmaya dahil edildi. Venlafaksin (3 ay boyunca günde 225 mg) hastalara verildi. Açlık kan örnekleri çalışmanın başlangıcında ve 3 ayın sonunda alındı. Biyokimyasal parametreler, serum nesfatin-1, nitrik oksit ve ghrelin düzeyleri analiz edildi.

Bulgular: Üç aylık tedavi sonunda hastaların prognozu HAM-D ölçeği ile değerlendirildi, 36.6±1 den 15.9±0.6 (P=0.04)'e doğru iyileşmeler gözlendi. MDB hastalarında tedavi sonrasında nesfatin-1 (P=0.001) ve ghrelin (P=0.001) düzeyleri anlamlı oranda azalırken, nitrik oksit düzeyi (P=0.04) anlamlı oranda artmıştır.

Sonuç: Venlafaksin tedavi sonrasında HAM-D ölçeğindeki ilerlemeye ek olarak nesfatin-1'in azalarak nitrik oksitin ise artarak normal değerlere doğru düzelmesi tedavi cevabının değerlendirilmesinde önemli bir kriter olabilir.

MDD is a severe psychiatric disorder that characterized by impaired mood and reduced of interest or pleasure in daily activities, and accompanied by weight change, sleep disturbance, fatigue, reduced physical capacity, developing countries, MDD prevalence rates are high and increasing continuously. The interesting point is the relationships between nesfatin-1 and MDD. The impaired food intake and energy regulation changes are commonly seen problems in patient with MDD⁹. Barim et al¹⁰ have studied the change in ghrelin level, which stimulate food intake in contrast to nesfatin-1, in response to the citolopram treatment. They observed an increase in body weight and decrease ghrelin level following depression treatments.

The nitric oxide (NO) level in MD D patients and its response to treatment is other important point to be clarified in this study. This is because, NO may have an important role in pathophysiology of depression. In addition, it has also been suggested that NO could be a criteria in treatment and following prognosis in depressive patients¹¹. It should be emphasize that effects of treatment on nesfatin-1 and NO levels has not been studied in patients with MDD. There is one study, performed to show the nesfatin-1 level in patient with MDD⁸. However, this study contains only basal high nesfatin-1 values in MDD patients. In this study we concerned the relation between nesfatin-1, NO, ghrelin levels and MDD.

We were purposed to examine the effects of three months of venlafaxine treatment on nesfatin-1, NO and ghrelin levels in patient with MDD to find a criteria used to evaluate the effectiveness of MDD treatment.

The sample size was determined by being used power analysis. A total of 60 subjects were participated in this study: 20 MDD patients (12 female and 8 male) and 40 control subjects (22 female and 18 male). For the first time MDD diagnosed patients were participated to this study. The MDD patients were chosen using diagnostic and statistical manual of mental disorderfourth edition (DSM-IV) criteria¹². The patients were participated to Hamilton Depression Rating Scale (HAMD) before and after the treatment to evaluate the patients' response to applied treatment¹³.

They were randomly assigned to receive oral treatment with Venlafaxine (Efexor, Wyeth) 225 mg/day, the dosage that has been shown to be the most effective in resistive MDD treatment¹⁴. The body mass index and age were similar in control group and MDD group. The control group was chosen from healthy subjects with taking no alcohol or smoking or taking any medication or severe illness including metabolic and psychiatric. Blood samples were drawn at study entry and after 3 months of therapy. After an overnight fast, a 5 ml venous blood sample was obtained between 8:00 AM and 10:00 AM, always at approximately the same time in the morning to avoid reductions in serum hormones levels over time. Blood samples were taken into the tube contaminated with the aprotinin to prevent desaturation of proteins. The samples were separated by centrifugation (4500 rpm for 5 minutes at 4°C) and stored at −20°C and analyzed immediately at the end of study (Hettich, Zentrifugen Universal 32 R, Germany).

The biochemical parameters (including cholesterol, triglyceride, HDL, LDL) were analyzed using OLYMPUS AU400 (Japan). Acylated ghrelin (SPI BIO CATT NO: A05119), des-acylated ghrelin (SPI BIO CATT NO: A05119) (SPI BIO, Bertin Pharma Biotech, Montignyle Brettoneux, France) and nesfatin-1 (RAY BIO CATT NO: EIA-NES-1) were analyzed using ELISA method. Total ghrelin was obtained from the sum of acylated ghrelin and des-acylated ghrelin. All analysis performed in the same experimental set in a blind fashion. NO determination was made using spectrophotometric Griess reaction. Intra- and interassay coefficients of variation were 8.1% and 8.3% for acylated ghrelin and 3.2% and 3.8% for desacylated ghrelin, respectively. Care was taken to perform the measurements with kits from the same company, as different commercial ghrelin kits measure the same biological sample differently. Intra- and interassay coefficients of variation were below %10 and below 15% for nesfatin-1, respectively. Nesfatin-1 values were linear between 1-100 ng/mL.

Values are expressed as means±SEM. The Kolmogorov–Smirnov Z test showed that the data were normally distributed Therefore. within-group comparisons of data at baseline and study end were assessed using the Paired t test. Unpaired t test used to assess between-group data and P<0.05 was considered significant.

Büyütmek İçin Tıklayın

Figure 1: Nesfatin-1 (A) and nitric oxide (B) values (mean±SEM) for control group, for MDD group pretreatment and post-treatment (a: significance between control and pre-treatment group. b: significance between pre and post treatment groups. c: significance between post-treatment and control groups).

NO for the control, before and after treatment are shown in Figure. The NO level was markedly low (P=0.001) in MDD patients group before treatment compared to control values: 2.2±0.5 nmol/L and 6.2±0.3 nmol/L, respectively (Figure 1). Importantly, after treatment, NO level increased to 3.3±0.5 nmol/L (P=0.04) (Figüre). However, NO was still significantly lower than the control group level (P=0.001) (Figüre)

In MDD patients group, before treatment, total ghrelin levels was markedly lower than the control group: 40.6±7.7 pg/ml vs 316.9±49.7 pg/ml, respectively (P=0.001) and it decreased significantly to 31.8±4.1 pg/ml, after treatment (P=0.001) (Table 1).

Büyütmek İçin Tıklayın

Table 1: The anthropometric and biochemical characteristics of the subjects (age, weight and body mass index, BMI), total ghrelin and biochemical parameters in patients with MDD before and after treatment and control subjects

The close relationship between nesfatin-1 and central nervous system hormones has been reported¹⁶. Importantly, the interaction of nesfatin-1 and central nervous system hormones has an important role in etiology of depression⁸. A markedly high nesfatin-1 level found in raphe nucleus neurons and locus coeruleus neurons of stressed rat compared to nonstressed rat¹⁷. This is important that locus coeruleus neurons have a powerful regulatory role on many mental functions known to be dysregulated in MDD¹⁸. In addition, raphe nucleus, which is the main source of serotonergic innervations in the brain, is the primary neurotransmitter accused for some metabolic and psychiatric changes including, appetite, energy, sleep, mood, libido and cognitive function changes in MDD¹⁹.

It is suggested that an increase in nesfatin-1 level may result an increase in anxiety via affecting melanocortin system²⁰. In clinical medicine, nesfatin-1 level could be important criteria to describe the patient prognoses and effectiveness of treatments. In previous study performed in epileptic patients, significant decreases in nesfatin-1 level reported following anti antiepileptic treatment⁷.

It has been suggested that ghrelin and nesfatin-1 could be closely related in ethiopathologies of psychiatric diseases in addition to their effects on appetite and food intake regulation^7,10. It is well known that ghrelin and nesfatin-1 is adversely affecting hormones²¹. The anorectic effect of nesfatin-1 has been shown after directly administering it into the brain of rodents¹. In literature, it is well known that ghrelin increases food intake in normal condition^3,10.

The results of a study performed in rodent suggested that ghrelin has antidepressive and depressiongenic effects²². In this study, basal ghrelin level of MDD patients was markedly lower than the control group, which could be the results of the depression^7,10. The lower ghrelin level before and after treatment could be related with the low antioxidant capacity, which is know to be reduced in depressive patients. Importantly, it has been shown that ghrelin has important effects on neuroprotection²³.

Despite the decrease in ghrelin level after treatment, we have observed increase in body weight (Table 1). It might be expected decrease ghrelin level results decrease in body weight rather than increases. The increased body weight during treatment period may be related with the reduced nesfatin-1 level or direct effects of drug affecting metabolic rate²⁴. In addition, it is also be emphasize that NO is an important regulatory factor in food intake²⁵. It is known that basal metabolic rate is one of the important factors in body weight regulation. The main reasons for weight gain in MDD patients after treatment are increased caloric intake, reduced energy expenditure or a combination of both. Venlafaxine may have important effects on basal metabolic rate and physical activity²⁶.

In this study, serum NO levels, before and after treatment, were measured and it was found to be markedly low in depressive patients. Importantly, NO level increased significantly after treatment, but it was still lower than the control levels. In depressive patients, end-production of NO metabolism has been shown to be high in some studies²⁷. In contrast, low NO levels in depressive patients compared to normal subjects has been reported²⁸. Interestingly, increased NO levels results a suicide attempt especially in mood disorders and schizophrenia patients²⁹. Thus, evaluation of NO level could be important criteria in depressive patients prognosis²⁷. However, the clear and satisfactory explanation in NO level and depressive patients has not been documented yet.

In this study, three months of venlafaxine treatment associated with significant improvements in nesfatin-1 and NO levels compared to their basal values over a three months period. In this regard, nesfatin-1 and NO could be useful markers to evaluate the effectiveness of treatment and prognosis of MDD in addition to the other parameters. However, further studies with a large number of sample size and with a longer treatment duration are required to understand the factors affecting nesfatin-1, ghrelin and NO metabolism and their roles in the etiology and also in prognosis of MDD.

Acknowledgement
This study financially supported by FUBAP (Firat University Scientific Research Support Unit, Project No: 1878) for master project.

1) Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin- 1 as a satiety molecule in the hypothalamus. Nature 2006; 443: 709–712.

2) Yosten GL, Samson WK, Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am J Physiol Regul Integr Comp Physiol 2009; 297: 330-336.

3) Nonogaki K, Ohba Y, Sumii M, et al. Serotonin systems upregulate the expression of hypothalamic NUCB2 via 5- HT2C receptors and induce anorexia via a leptinindependent pathway in mice. Biochem Biophys Res Commun 2008; 372: 186-190.

4) Su Y, Zhang J, Tang Y, et al. The novel function of nesfatin-1: anti-hyperglycemia. Biochem Biophys Res Commun 2010; 391: 1039-1042.

5) Algül S, Özçelik O. Obezite tedavisi için umut verici yeni bir peptid: Nesfatin-1. F Ü Sağ Bil Tıp Derg 2012; 26: 143-148.

6) García-Galiano D, Navarro VM, Roa J, et al. The anorexigenic neuropeptide, nesfatin-1, is indispensable for normal puberty onset in the female rat. J Neurosci 2010; 30: 7783-7792.

7) Aydin S, Dag E, Ozkan Y, et al. Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders. Mol Cell Biochem 2009; 328: 49-56.

8) Ari M, Ozturk OH, Bez Y, et al. High plasma nesfatin-1 level in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 497-500.

9) Mischoulon D, Eddy KT, Keshaviah A, et al. Depression and eating disorders: Treatment and course. J Affect Disord 2010; 130: 470-477.

10) Barim AO, Aydin S, Colak R, et al. Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment. Clin Biochem 2009; 42: 1076- 1081.

11) Suzuki E, Yagi G, Nakaki T, et al. Elevated plasma nitrate levels in depressive states. J Affect Disord 2001; 63: 221–224.

12) American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition Washington DC: American Psychiatric Press 1994.

13) Hamilton M, A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.

14) Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a metaanalysis. BJ Psych 2002; 180: 396-404.

15) Bez Y, Ari M, Ozturk OH, et al. Plasma nesfatin-1 level may be associated with disease severity in patient with panic disorders. Bull Clin Psycopharmacol 2010; 20: 288-292.

16) Yoshida N, Maejima Y, Sedbazar U, et al. Stressorresponsive central nesfatin-1 activates corticotropinreleasing hormone, noradrenaline and serotonin neurons and evokes hypothalamic-pituitary-adrenal axis. Aging (Albany NY) 2010; 2: 775-784.

17) Goebel M, Stengel A, Wang L, et al. Restraint stress activates nesfatin-1-immunoreactive brain nuclei in rats. Brain Res 2009; 1300: 114-124.

18) Leonard BE, The role of noradrenaline in depression: a review. J Psychopharmacol 1997; 11: 39–47.

19) Kranz GS, Kasper S, Lanzenberger R, Reward and the serotonergic system. Neuroscience 2010; 166: 1023–1035.

20) Chaki S, Okubo T, Melanocortin-4 receptor antagonists for the treatment of depression and anxiety disorders. Curr Top Med Chem 2007; 7: 1145–1151.

21) Stengel A, Goebel M, Wang L, et al. Ghrelin, des-acyl ghrelin and nesfatin-1 in gastric X/A-like cells: role as regulators of food intake and body weight. Peptides 2010; 31: 357-369.

22) Kanehisa M, Akiyoshi J, Kitaichi T, et al. Administration of antisense DNA for ghrelin causes an antidepressant and anxiolytic response in rats. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1403–1407.

23) Lutter M, Sakata I, Osborne-Lawrence S, et al. The orexigenic hormone ghrelin defends against depressive symptoms of chronic stres. Nat Neurosci 2008; 11: 752– 753.

24) Kennedy SH, Konarski JZ, Segal ZV, et al. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry 2007; 164: 778-788.

25) Gaskin FS, Farr SA, Banks WA, et al. Ghrelin-induced feeding is dependent on nitric oxide. Peptides 2003; 24: 913-918.

26) Soreca I, Mauri M, Castrogiovanni S, et al. Measured and expected resting energy expenditure in patients with bipolar disorder on maintenance treatment. Polar Disord 2007; 9: 784-788.

27) Papageorgiou C, Grapsa E, Christodoulou NG, et al. Association of serum nitric oxide levels with depressive symptoms: a study with end-stage renal failure patients. Psychother Psychosom 2001; 70: 216-220.

28) Wallerath T, Witte K, Schafer SC, et al. Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension. Proc Natl Acad Sci USA 1999; 96: 13357–13362.

29) Lee BH, Lee SW, Yoon D, et al. Increased plasma nitric oxide metabolites in suicide attempters. Neuropsychobiol 2006; 53: 127–132.